melflufen + dexamethasone + daratumumab

A combination regimen composed of **melflufen (melphalan flufenamide)**, **dexamethasone**, and **daratumumab** used in the treatment of **relapsed/refractory multiple myeloma (RRMM)**, especially in patients previously treated with or refractory to immunomodulatory agents and/or proteasome inhibitors. - **Melflufen** is a first-in-class peptide-drug conjugate; it is an alkylating agent that releases melphalan inside cells to cause cytotoxic DNA damage. - **Dexamethasone** is a synthetic glucocorticoid corticosteroid with anti-inflammatory and immunosuppressive effects that also induces apoptosis in certain hematologic malignancies. - **Daratumumab** is a monoclonal antibody targeting CD38 expressed on plasma cells, mediating cytotoxicity through immune effector mechanisms. This triplet regimen has shown improved progression-free survival and higher response rates over daratumumab and dexamethasone alone in clinical trials, with a safety profile primarily marked by manageable hematological toxicities such as neutropenia and thrombocytopenia[1][3][5]. **Developed and studied primarily for multiple myeloma.**

Brand names

Pepaxto (for melflufen)Darzalex (for daratumumab)Darzalex Faspro (for daratumumab plus hyaluronidase-fihj)None for the fixed three-drug combination

Other names

melphalan flufenamide + dexamethasone + daratumumab